Using Wild-Type and Transgenic Rodent Models to Tackle Immunological Evaluation Challenges of Collagen-Based...

Area of Science:

• Biomaterials Science
• Immunotoxicology
• Transgenic Animal Models

Background:

• Current immunotoxicity testing for collagen devices uses rodent models, potentially introducing interspecies bias.
• Human Type III collagen transgenic mice were developed to better mimic human immune responses.

Purpose of the Study:

• To evaluate the immunotoxicity of human collagen and recombinant/cell-engineered collagens (CCs) using a novel human Type III collagen transgenic mouse model.
• To compare immune responses in transgenic mice versus wild-type controls according to ISO/TS 10993-20 guidelines.

Main Methods:

• Developed a human Type III collagen transgenic mouse model by integrating the human COL3A1 gene into C57BL/6J mice.
• Assessed immunotoxicity by injecting collagens and controls, monitoring serum antibody levels (0-90 days), and performing terminal analyses (30 & 90 days) of splenic lymphocyte subsets and tissue reactions.
• Confirmed gene expression via mRNA and peptide analysis.

Main Results:

• Transgenic mice exhibited lower serum antibody levels compared to wild-type controls.
• Wild-type mice showed significantly higher antibody responses at 60 days, indicating altered immune recognition in transgenic models.
• Recombinant/cell-engineered collagens induced only transient immune responses without sustained activation.

Conclusions:

• The human Type III collagen transgenic mouse model demonstrates a modified immune recognition pattern, offering a more relevant platform for immunotoxicity assessment.
• This model provides valuable insights for refining immunoevaluation strategies for collagen-based medical devices.
• Recombinant and cell-engineered collagens appear to have a favorable immunotoxicological profile in this model.